Market Cap
$747.2M
OLMA
Olema Pharmaceuticals, Inc.
$8.38 ▲ +1.33%
Prev close $8.27Market cap$747.2M
ConsensusStrong Buy
12-mo target$36.50 (+335.6%)
▲ Bullish
Analyst conviction 9/10
30 New Institutional Positions20 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on OLMA right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (89%)
Inst. Holders
50 funds
Inst. Value
$716.9M
Inst. Activity
30 buys / 20 sells
Insider Activity
$0.00 buy / $1.2M sell
Insider Net $
-$1.2M
SEC Reports
8
Press Releases
5
Price chart 30d -22.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 short_volume
Short Volume: OLMA — 67.0% short (0.4M / 0.6M)
Short: 419,652 | Exempt: 0 | TRF Vol: 626,394 | Short Ratio: 67.0% | Off-exchange volume (dark pool
Sep 1, 2026 Insider
Aug 10, 2026 SEC O'Byrne Jason was granted 650,000 shares
CHIEF FINANCIAL OFFICER
Olema Pharmaceuticals reported a Q2 2026 net loss of $63.2M, wider than the $43.8M loss in Q2 2025, driven by increased
8-K — Impact 5/10
Olema Oncology's Q2 2026 net loss widened to $63.2M (vs $43.8M a year ago) on higher R&D and G&A spending, but cash of $
PRESS-RELEASE — Impact 4/10
Institutional cluster for OLMA shows net selling of ~$27.4M in Q2 2026, driven by Jennison Associates' full exit of a $2
INST-CLUSTER — Impact 6/10
Jul 24, 2026 Insider
Harmon Cyrus sold 12,500 shares
Director @ $11.71 ($146.4K)
Jul 23, 2026 Insider
Harmon Cyrus sold 12,500 shares
Director @ $11.58 ($144.7K)
Jun 30, 2026 Inst.
MORGAN STANLEY — ADD
1,832,269 shares ($22.9M)
Analyst ratings buy % -4.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
89% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 14, 2026 | Stifel | MAINTAIN | Buy | 54% |
| Aug 13, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 11, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Aug 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 13, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 10 | 2 | 0 | 0 | 89% | |
| Aug 1, 2026 | 6 | 10 | 2 | 0 | 0 | 89% | |
| Jul 1, 2026 | 6 | 10 | 2 | 0 | 0 | 89% | |
| Jun 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| May 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% |
Price targets
Where 10 covering analysts think OLMA trades over the next 12 months.
$36.50 +335.6% upside Strong Buy
Current$8.38 Low$16.00 Median$38.00 High$59.00 10 analysts
$16.00$59.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 2 bullish, 1 bearish, 0 mixed, 5 neutral · avg impact 4.8/10.Plus 5 press releases.
NEUTRAL8-K5/10
Olema Pharmaceuticals reported a Q2 2026 net loss of $63.2M, wider than the $43.8M loss in Q2 2025,
Aug 10, 2026
NEUTRALPRESS-RELEASE4/10
Olema Oncology's Q2 2026 net loss widened to $63.2M (vs $43.8M a year ago) on higher R&D and G&A spe
Aug 10, 2026
BEARISHINST-CLUSTER6/10
Institutional cluster for OLMA shows net selling of ~$27.4M in Q2 2026, driven by Jennison Associate
Aug 9, 2026
BULLISH8-K6/10
Olema Pharmaceuticals announced a clinical trial collaboration and supply agreement with Bayer to ev
May 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
short_volume
Short Volume: OLMA — 67.0% short (0.4M / 0.6M)
Short: 419,652 | Exempt: 0 | TRF Vol: 626,394 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: OLMA — 65.2% short (0.4M / 0.6M)
Short: 362,859 | Exempt: 0 | TRF Vol: 556,356 | Short Ratio: 65.2% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: OLMA — 56.2% short (0.5M / 0.8M)
Short: 465,023 | Exempt: 0 | TRF Vol: 827,283 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Sep 2, 2026
other
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmac
Aug 31, 2026
other
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmace
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.63 | $-0.73–$-0.50 | -29.4% | +1.7% | 1↑ 7↓ | $0.0B | 9 |
| Next Q | $-0.66 | $-0.73–$-0.52 | -31.2% | +2.0% | 1↑ 7↓ | $0.0B | 9 |
| Current FY | $-2.38 | $-2.69–$-1.92 | -27.2% | +1.8% | 1↑ 7↓ | $0.0B | 9 |
| Next FY | $-2.64 | $-3.09–$-2.04 | -10.9% | +1.9% | 1↑ 7↓ | $0.0B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.634 | — |
| 7d ago | $-0.631 | -0.003 |
| 30d ago | $-0.645 | +0.011 |
| 60d ago | $-0.579 | -0.055 |
| 90d ago | $-0.579 | -0.055 |
Institutional ownership
Which big funds own OLMA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $716.9M total value (57,292,490 shares) as of 2026-Q2. Top holders: FMR, Jupiter, BlackRock,. Net buying activity: 30 institutions added/increased vs 20 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 12,143,062 | $151.9M | 21.2% | — |
| Jupiter Topco LLC | 7,094,413 | $88.8M | 12.4% | — |
| BlackRock, Inc. | 6,714,691 | $84.0M | 11.7% | — |
| STATE STREET CORP | 4,316,058 | $54.0M | 7.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,341,217 | $41.8M | 5.8% | — |
| FRANKLIN RESOURCES INC | 2,349,586 | $29.4M | 4.1% | — |
| MORGAN STANLEY | 1,832,269 | $22.9M | 3.2% | ADD +50.7% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,819,029 | $22.8M | 3.2% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,663,218 | $20.8M | 2.9% | DOUBLED +180.5% |
| GOLDMAN SACHS GROUP INC | 1,567,979 | $19.6M | 2.7% | ADD +50.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 1,215,690 | 1,832,269 | +50.7% | $22.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | 593,031 | 1,663,218 | +180.5% | $20.8M |
| GOLDMAN SACHS GROUP INC | ADD | 1,045,589 | 1,567,979 | +50.0% | $19.6M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 1,082,434 | 1,416,533 | +30.9% | $17.7M |
| Point72 Asset Management, L.P. | DOUBLED | 71,107 | 1,070,949 | +1406.1% | $13.4M |
| AMERIPRISE FINANCIAL INC | DOUBLED | 57,362 | 840,646 | +1365.5% | $10.5M |
| Woodline Partners LP | TRIM | 1,482,030 | 751,030 | -49.3% | $9.4M |
| Qube Research & Technologies Ltd | DOUBLED | 312,812 | 663,319 | +112.1% | $8.3M |
| CITADEL ADVISORS LLC | TRIM | 905,332 | 641,828 | -29.1% | $8.0M |
| Hudson Bay Capital Management LP | DOUBLED | 154,770 | 566,400 | +266.0% | $7.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 31 transactions. Net -$1.2M — $0.00 bought, $1.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | O'Byrne Jason | CHIEF FINANCIAL OFFICER | AWARD | 650,000 | — | — |
| Jul 24, 2026 | Harmon Cyrus | Director | SELL | 12,500 | $11.71 | $146.4K |
| Jul 23, 2026 | Harmon Cyrus | Director | SELL | 12,500 | $11.58 | $144.7K |
| Jun 18, 2026 | Graham G. Walmsley | Director | AWARD | 29,500 | — | — |
| Jun 18, 2026 | RAPPAPORT ANDREW | Director | AWARD | 29,500 | — | — |
| Jun 18, 2026 | Raman Prakash | Director | AWARD | 29,500 | — | — |
| Jun 18, 2026 | Horning Sandra | Director | AWARD | 29,500 | — | — |
| Jun 18, 2026 | Larson Yi | Director | AWARD | 29,500 | — | — |
| Jun 18, 2026 | CLARK IAN T | Director | AWARD | 29,500 | — | — |
| Jun 18, 2026 | Hrustanovic Gorjan | Director | AWARD | 29,500 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for OLMA.
Shares short
16,068,469
Settlement Sep 15, 2026
Change vs prior
+2.6%
Semi-monthly cycle
Days to cover
15.9
At avg daily volume
Of shares outstanding
≈18.4%
Estimate — not % of float
All OLMA filing & press-release reports (13)
- 8-K reportAug 10, 2026
- PRESS-RELEASE reportAug 10, 2026
- INST-CLUSTER reportAug 9, 2026
- 8-K reportMay 26, 2026
- PRESS-RELEASE reportMay 26, 2026
- 8-K reportMay 21, 2026
- PRESS-RELEASE reportMay 21, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- DEFA14A reportApr 29, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportMar 16, 2026